Compare AbCellera Biologics Inc (ABCL) vs Crocs, Inc. (CROX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Crocs, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Crocs, Inc. trades at $120.23 (market cap $6.19B). The key difference: Crocs, Inc. is far larger — about 2.6× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | CROX | |
|---|---|---|
Market Cap | $2.35B | $6.19B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $127.77 |
52-Week Low | $2.78 | $73.39 |
Enterprise Value | $1.99B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Crocs (CROX) trades at $124.55, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $4.04B for 2025 but posted a net loss of $81.20M, with negative profit margins. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 51.35% buy rating and consensus price target of $131.75. News highlights include marketing initiatives like TikTok microdramas and expansion in Asian markets.
The outlook for CROX is mixed: strong brand momentum and earnings beats support upside potential, but profitability concerns and negative net income margins pose risks. Investors should weigh growth initiatives against margin pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
